Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $5.8M Series A financing. Participants include Truffle Capital, Aurinvest Capital and Financière Boscary.